Company Overview and News
In this age of the #MeToo movement, HR departments around the world are under siege. No one trusts human resources because they’re seen to cover up the misdeeds of upper management rather than champion the causes of the men and woman way down the pecking order. Things have gotten so bad that an app’s been created called Blind that allows employees to complain about their companies anonymously without being found out.
AMZN ADPVV DATA CDAY WDAY ADP 0550 PAYC TNET
TriNet Group, Inc. (TNET - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at TNET given that, according to its RSI reading of 29.99, it is now in oversold territory.
Tensions between the world’s top two economies intensified on Monday when the Trump administration announced fresh 10% tariff on $200 billion of imports from China and threatened additional tariff son $267 billion worth of goods in case China takes retaliatory action.
CNDT UNP HSII CLH TNET
2018-09-17 investorplace - 3
No investment strategy suits all the people all the time. This is particularly true for young investors in their 20s and 30s. Youth not only has social advantages; it can provide significant margin for your portfolio to grow. As such, high-growth stocks are ideal for the young-adult, millennial demographic.
SQ GE GEC MHVYF ACBFF K CTRL CVNA M CGC GLD CMG VYGR ACB AMZN KGC O87 WEED GNE TNET 7011
2018-09-13 investorplace - 1
There’s no doubt that we continue to be in a growth-fueled market. This hasn’t always been the case. In case you’ve forgotten, after the financial meltdown, it was dividend stocks that were the ‘new’ growth stocks. Everyone was scrambling for dividends, and not surprisingly, many stocks began to offer tantalizing dividends.
AMZN TPIC CTRL SNE ABMD SNEJF TNET
The portfolio continues to be very concentrated with the top five positions accounting for ~29% of the 13F portfolio.
FB SERV IBKR GOOG MHFI SPGI CME AGN AMT AVGO WSH ICE FIS INTC BIDU CBRE ECL AWI EFX VRSN WLTW ZTS V 7018 CBG PRI GOOGL CACC ADI BRCM TNET
TriNet Group, Inc. (TNET - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because TNET recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
OHI BFS TNET
Good day. And welcome to the TriNet's 2018 Second Quarter Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note today's event is being recorded.
Per the latest Earnings Outlook, 217 S&P 500 companies (who collectively account for 54.1% of the index’s total market capitalization) have already reported results. Total earnings of these companies increased 21.8% from the same period last year on 8.8% higher revenues, with 81.6% beating EPS estimates and 72.8% beating revenue estimates. Of these 217 companies, 63.1% beat both EPS and revenue estimates.
EA FDC NVR BAH BKI TRN TNET
DUBLIN, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- TriNet Group, Inc. (NYSE:TNET), a leading provider of comprehensive human resources solutions for small to midsize businesses, today announced that on July 1, 2018 the Internal Revenue Service (IRS) designated a TriNet subsidiary as a Certified Professional Employer Organization (CPEO). CPEO is a federal certification program managed by the IRS that compliments existing state licensing programs for PEOs, like TriNet.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TNET / TriNet Group, Inc. on message board site Silicon Investor.
as of ET